These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1302 related articles for article (PubMed ID: 8895549)
1. Immune response during tumor therapy with antibody-superantigen fusion proteins. Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549 [TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740 [TBL] [Abstract][Full Text] [Related]
3. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219 [TBL] [Abstract][Full Text] [Related]
4. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621 [TBL] [Abstract][Full Text] [Related]
5. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens. Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366 [TBL] [Abstract][Full Text] [Related]
6. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390 [TBL] [Abstract][Full Text] [Related]
7. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129 [TBL] [Abstract][Full Text] [Related]
8. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661 [TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049 [TBL] [Abstract][Full Text] [Related]
12. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects. Sundstedt A; Celander M; Hedlund G Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798 [TBL] [Abstract][Full Text] [Related]
13. Superantigens anergize cytokine production but not cytotoxicity in vivo. Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912 [TBL] [Abstract][Full Text] [Related]
14. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731 [TBL] [Abstract][Full Text] [Related]
16. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731 [TBL] [Abstract][Full Text] [Related]
17. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; He L; Wang J; Cao X J Cancer Res Clin Oncol; 2001 Dec; 127(12):718-26. PubMed ID: 11768611 [TBL] [Abstract][Full Text] [Related]
19. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087 [TBL] [Abstract][Full Text] [Related]
20. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Rosendahl A; Kristensson K; Carlsson M; Skartved NJ; Riesbeck K; Søgaard M; Dohlsten M Int J Cancer; 1999 Mar; 81(1):156-63. PubMed ID: 10077167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]